LAPATINIB PRI RAKE MOLOChNOY ZhELEZY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Lapatinib is a new anticancer drug, dual inhibitor of tyrosine kinase receptors HER1/HER2. Now, it is widely used in combination with capecitabine in advanced and/or metastatic breast cancer with HER2 receptor overexpression in patients previously treated with trastuzumab and resistance to the latter. The intensive studies to assess the effectiveness of lapatinib in combination with various cytotoxic drugs, hormonal treatment, as well as with other targeted agents are continued. The potentials for the use of lapatinib as adjuvant and neoadjuvant therapy are discussed.

Толық мәтін

Рұқсат жабық

Авторлар туралы

I. Fray

N. Perevodchikova

Әдебиет тізімі

  1. Chu I., Blackwell K., Chen S., et al. The Dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation - and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer. Res. 2005; 65: 18-25
  2. Atalay G., Cardoso F., Awada A., et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann. Oncol. 2003; 14: 1346-63.
  3. Hung M.C., Lau Y.K. Basic science of HER-2/ neu: a review. Semin. Oncol. 1999; 26: 51-9.
  4. Rowinsky E.K. The ErbB family: targets for therapeutic development against cancer and therapeutic strategiesusing monoclonal antibodies and tyrosine kinase inhibitors. Annu. Rev. Med. 2004; 55: 433-57.
  5. Yoshinori I., Nahomi T., Tsutomu S., et al. Does Lapatinib, a Small-Molecule Tyrosine Kinase Inhibitor, Constitute a Breakthrough in the Treatment of Breast Cancer? Breast Cancer. 2007; 14(2): 156-62.
  6. Burris H.A. 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004; 9(suppl 3): 10-5.
  7. Yarden Y., Sliwkowsky M.X. Untangling the ErbB signalling network. Nat. Rev. Cell. Mol. Biol. 2001; 2: 127-37.
  8. Фролова М.А., Тюляндин С.А. Лапатиниб в лечении рака молочной железы: история клинического развития препарата и собственный опыт применения. РМЖ. 2008; 13; 921.
  9. Menard S., Balsari A., Casalini P., et al. HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin. Cancer Res. 2002; 8: 520-25.
  10. Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61: 7196-203.
  11. Versola M., Burris H., Jones S., et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J. Clin. Oncol. 2004; 22.
  12. Gelmon K.A., Boyle F., Kaufman B., et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+-metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. http://meetinglibrary.asco.org/content/102986-114 (Accessed on August 12, 2013).
  13. Pivot X., Semiglazov V., Zurawsky B., et al. CEREBEL (EGF111438): An open-label randomized phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treated with lapatinib plus capecitabine versus trastuzumab plus capecitabine. Ann. Oncol. 2012; 23(9 suppl): LBA11 [abstact LBA11 from 2012 ESMO meeting].
  14. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008; 112(3): 533-43.
  15. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006; 355: 2733-43.
  16. Di Leo A., Gomez H., Aziz Z., et al. Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. J. Clin. Oncol. 2008; 5544-52.
  17. Cameron D.A., Stein S. Drug insight: intracellular inhibitors of HER-2-clinical development of lapatinib in breast cancer. Nat. Clin. Prac. Oncol. 2008; 5(9): 512-19.
  18. Wenham N., D'Hondt V., Piccart M.J. HER-2-positive breast cancer: from trastuzumab to innovatory anti-HER-2 strategies. Clin. Breast Cancer. 2008; 8(1): 38-49.
  19. Carey L.A., Berry D.A., Ollila D.W., et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J. Clin. Oncol. 2013; 31(suppl): abstr 500.
  20. Ollila D.W., Berry D.A., Cirrincione C., et al. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). J. Clin. Oncol. 2013; 31(suppl): abstr 501.
  21. Papadimitriou C.A., Sarosiek T., Pikiel J., et al. A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC). J. Clin. Oncol. 2013; 31 (suppl): abstr 516.
  22. Chew H.K., Schwartzberg L.S., Badarinath S., et al. Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2013; 31 (suppl): abstr 621.
  23. Untch M., Loibl S., Bischoff J., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (Gepar Quinto, GBG 44): randomized phase 3 trial. Lancet Oncol. 2012; 13: 135-44.
  24. Guerra Y.C., Chan A., Finkelstein D.M., et al. Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2-ve BC): Analysis of patients in the TEACH trial. J. Clin. Oncol. 2013; 31(suppl): abstr 628.
  25. Moy B., Goss P.E. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006; 11 (10): 1047-57.
  26. Bacus S.S., Trusk P., Lyass L., et al. Inhibition of ErbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity. Breast Cancer Res. Treat. 2006; 100(Suppl. 1) abstr. 304.
  27. Perez E.A., Byrne J.A., Hammond I.W. et al. Results of analysis of cardiac function in 2,812 patients treated with lapatinib. J. Clin. Oncol. 2006; 24(S18): abstr. 583.
  28. Blackwell K.L., Miles D., Gianni L., et al. Primary results from EMILIA, phase III of trastuzumab emtansine (T-DM1) vs. capecitabine and lapatinib in Her2+ locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane. J. Clin. Oncol. 2012; 30(suppl): abstr LBA1.
  29. Переводчикова Н.И., Стенина М.Б. Лекарственная терапия рака молочной железы. Практика. 2014. С. 99-100.
  30. Guarneri V., Frassoldati A., Piacentini F., et al. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER-2-positive operable breast cancer (CHERLOB trial). Clin. Breast Cancer. 2008; 8(2): 192-94.
  31. ALTTO trial findings raise questions on approach to drug development in early-stage breast cancer. ASCO 2014. Abstract LBA4.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>